Cannabis Alert: SHOCKING Research Means Huge Pot Profits
That’s the message coming out of Michigan State University this week after researchers published a study showing that THC, the chemical responsible for the euphoric high in marijuana, may help HIV patients keep mental stamina longer.
The study looked at white blood cell samples from HIV patients and studied the differences in monocytes, or inflammatory cells, between those who use pot and those who don’t.
The results were significant.
“The patients who didn’t smoke marijuana had a very high level of inflammatory cells compared to those who did use,” said Norbert Kaminski, one of the researchers behind the study. “In fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.”
The implications go far beyond HIV patients, though.
It’s just that the anti-inflammatory properties of cannabis are much easier to spot in immunocompromised patients, like those with HIV.
Fact is, inflammation is why we age.
As we get older, our immune system functions differently. This occurs as pro-inflammatory molecules, called cytokines, are released in greater quantities than when we were young, leading to many age-related inflammatory diseases.
The research at Michigan State is just the most recent study to suggest that cannabis could have breakthrough anti-inflammatory properties for the pharmaceutical industry.
By slowing the inflammaging process, we could enjoy longer, healthier life spans.
This in turn would likely positively influence how long we can have active lives, as well as make a big dent in age-related health care expenses. The impact of healthy, productive older people on the economy as a whole would be huge.
As the weight of the evidence continues to show that cannabis has incredible pharma implications, the feds are having a harder time justifying marijuana’s Schedule I drug status. And lifting that status is the first step toward federal legalization of medical marijuana, a policy shift that would be huge for U.S. cannabis firms.
Because simply put, foreign cannabis companies — particularly those in Canada — have a huge legal advantage over U.S. pot firms.
In late November, Canada’s House of Commons passed Bill C-45 by a vote of 200-82.
The bill would legalize marijuana for recreational purposes, keeping Canada on track for the federal government’s plan to legalize cannabis use by July 2018. Now that Canada’s House of Commons has passed the bill, it’ll move on to the Senate. Big news is on its way soon.
At present however, only medical uses of marijuana are currently legal in Canada. But when that changes this summer, it’s going to unleash a huge profit opportunity.
Meanwhile, the prospect that cannabis could be the key to an anti-aging breakthrough in the very near term could do incredible things for your fortunes, as well as your health.
We’ll continue to follow the trend wherever it takes us, but one thing remains very clear right now: Canadian cannabis companies only have upside ahead of them.
I’m currently planning a fact-finding trip to Canada to meet with some of the companies up there — including new updates and recommendations.
I’ll keep you posted as things continue to materialize.
For Tomorrow’s Trends Today,
Editor’s note: Ray’s uncovered a SHOCKING admission by a U.S. government agency.
For the first time ever, the National Institutes of Health acknowledges marijuana can treat the world’s deadliest diseases… even cancer.